Hints and tips:
Related Special Reports
...The V&A in London is also in difficulties over treasures in its recent wonderful exhibition of Fabergé eggs, which ended some weeks ago....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Bernard Pécoul, head of the Drugs for Neglected Diseases Initiative, a Geneva-based non-profit organisation that helps develop better drugs for the world’s poor, is among those who would prefer to dispense...
...Graphics by Federica Cocco and Steven Bernard....
...And I’m thinking Denzel Washington for Hillcoat’s tough but caring boss Bernard Kantor… Mogul: …who tells Hatstand: “Kid, you’re the best we got....
...Pfizer was not alone. Bernard Munos, a former Eli Lilly executive who has studied 60 years of pharmaceutical innovation, says all big drug groups tried to scale up....
...Bernard Munos, a consultant to industry, praises larger companies such as GlaxoSmithKline and Johnson & Johnson for just such a shift to a more entrepreneurial, small-scale culture, which he says is beginning...
...Bernard Munos, a veteran industry expert on R&D, says the AstraZeneca approach fits Pfizer’s habit of going shopping for growth to cover up its R&D failings....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“The whole immuno-oncology area is exploding,” says John LaMattina, former head of research and development for Pfizer....
...The breakdown provided a measure of vindication to AstraZeneca, whose board had cited the political risks surrounding inversions as one of its reasons for rejecting Pfizer’s £69.4bn offer in May....
...In an unusual commitment between rivals, Johnson & Johnson will combine forces with Pfizer and Abbott to develop a macrofilaricide anti-worming pill to tackle river blindness and lymphatic filariasis....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...“As present, Wallonia represents the best-value proposition in Europe for the location of logistics activities,” says Bernard Piette, general manager of Logistics in Wallonia, a regional trade promotion...
...Mr Rowe draws a distinction between what he describes as the “ultra-rich”, who continue to buy large aircraft such as Bombardier’s Challenger 604 and the Gulfstream V, and the merely “moderately rich” who...
...Jean-Bernard Lévy, chief executive of Vivendi, welcomed the conclusion of the long-running talks: “We are very proud to welcome EMI into the Vivendi family....
...The fund also takes large long-term investment companies, with financial disclosure showing that Greenlight’s largest holdings are positions in Pfizer, Apple and Microsoft....
.... – Bernard Simon Pharma sector When Pfizer, one of the world’s largest pharmaceutical companies, unveiled plans in January this year to close its flagship research and development centre in Sandwich on...
...GapperBlog: Pfizer’s chief executive is painfully honest Jeffrey Kindler deserves points for honesty in declaring that he is departing as chairman and chief executive of Pfizer because he is exhausted...
...Mr Dunn said that tougher scrutiny of mergers by both the EU and the US was proving to be a big business source for the company, which was involved with everything from the combination of Wyeth and Pfizer...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Even more controversially, Bernard argues that perhaps Henry was right in assuming her guilt. Yet despite his scholarly rigour, Bernard himself is not immune to speculation....
International Edition